MX2021015137A - Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos. - Google Patents
Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos.Info
- Publication number
- MX2021015137A MX2021015137A MX2021015137A MX2021015137A MX2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A
- Authority
- MX
- Mexico
- Prior art keywords
- succinate prodrug
- prodrug
- compositions containing
- succinate
- nutricosmetics
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002407 ATP formation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201970384 | 2019-06-19 | ||
| DKPA201970382 | 2019-06-19 | ||
| DKPA201970383 | 2019-06-19 | ||
| PCT/EP2020/066923 WO2020254484A1 (en) | 2019-06-19 | 2020-06-18 | Succinate prodrug, compositions containing the succinate prodrug and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015137A true MX2021015137A (es) | 2022-01-18 |
Family
ID=71130953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015137A MX2021015137A (es) | 2019-06-19 | 2020-06-18 | Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11565998B2 (enExample) |
| EP (2) | EP4360708A3 (enExample) |
| JP (2) | JP7699551B2 (enExample) |
| KR (1) | KR102871719B1 (enExample) |
| CN (1) | CN113993842B (enExample) |
| AU (1) | AU2020298031B2 (enExample) |
| CA (1) | CA3143112A1 (enExample) |
| IL (1) | IL288990B2 (enExample) |
| MA (1) | MA56506A (enExample) |
| MX (1) | MX2021015137A (enExample) |
| WO (1) | WO2020254484A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL288990B2 (en) * | 2019-06-19 | 2025-09-01 | Abliva Ab | Succinate drug meters, preparations containing the succinate drug meters and its uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9612331D0 (en) | 1996-06-13 | 1996-08-14 | Leo Pharm Prod Ltd | Chemical compounds |
| AUPR059400A0 (en) | 2000-10-06 | 2000-11-02 | Bar-Ilan University | Formaldehyde-releasing prodrugs |
| CN106255509A (zh) * | 2014-04-08 | 2016-12-21 | 纽维制药有限公司 | 用于在归因于线粒体氧化磷酸化的复合体i相关损伤的乳酸性酸中毒或药物诱导的副作用的治疗中应用的琥珀酸酯前药 |
| CN106458957B (zh) * | 2014-04-08 | 2020-08-18 | 爱博利瓦有限公司 | 新型细胞可渗透琥珀酸化合物 |
| IL288990B2 (en) * | 2019-06-19 | 2025-09-01 | Abliva Ab | Succinate drug meters, preparations containing the succinate drug meters and its uses |
-
2020
- 2020-06-17 IL IL288990A patent/IL288990B2/en unknown
- 2020-06-18 MA MA056506A patent/MA56506A/fr unknown
- 2020-06-18 JP JP2021575316A patent/JP7699551B2/ja active Active
- 2020-06-18 MX MX2021015137A patent/MX2021015137A/es unknown
- 2020-06-18 CA CA3143112A patent/CA3143112A1/en active Pending
- 2020-06-18 US US17/615,408 patent/US11565998B2/en active Active
- 2020-06-18 EP EP24152013.9A patent/EP4360708A3/en not_active Withdrawn
- 2020-06-18 KR KR1020227002009A patent/KR102871719B1/ko active Active
- 2020-06-18 AU AU2020298031A patent/AU2020298031B2/en active Active
- 2020-06-18 WO PCT/EP2020/066923 patent/WO2020254484A1/en not_active Ceased
- 2020-06-18 CN CN202080043350.XA patent/CN113993842B/zh active Active
- 2020-06-18 EP EP20734337.7A patent/EP3986862B1/en active Active
-
2022
- 2022-09-14 US US17/944,751 patent/US12162824B2/en active Active
-
2024
- 2024-10-08 JP JP2024176276A patent/JP2025004155A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11565998B2 (en) | 2023-01-31 |
| US20220162162A1 (en) | 2022-05-26 |
| IL288990B2 (en) | 2025-09-01 |
| JP2025004155A (ja) | 2025-01-14 |
| EP4360708A2 (en) | 2024-05-01 |
| EP4360708A3 (en) | 2024-12-25 |
| KR102871719B1 (ko) | 2025-10-15 |
| JP2022538009A (ja) | 2022-08-31 |
| CN113993842A (zh) | 2022-01-28 |
| EP3986862B1 (en) | 2024-01-24 |
| KR20220024780A (ko) | 2022-03-03 |
| US20230033294A1 (en) | 2023-02-02 |
| US12162824B2 (en) | 2024-12-10 |
| EP3986862A1 (en) | 2022-04-27 |
| AU2020298031B2 (en) | 2025-12-18 |
| EP3986862C0 (en) | 2024-01-24 |
| CA3143112A1 (en) | 2020-12-24 |
| IL288990A (en) | 2022-02-01 |
| CN113993842B (zh) | 2024-07-16 |
| WO2020254484A1 (en) | 2020-12-24 |
| JP7699551B2 (ja) | 2025-06-27 |
| BR112021024510A2 (pt) | 2022-01-18 |
| AU2020298031A1 (en) | 2022-02-03 |
| IL288990B1 (en) | 2025-05-01 |
| MA56506A (fr) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| ZA202004729B (en) | Pharmaceutical compounds | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| AU2018231032A8 (en) | JAK inhibitors containing a 4-membered heterocyclic amide | |
| PH12017500367B1 (en) | Compounds that inhibit mcl-1 protein | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
| PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MX2017006649A (es) | Derivados de triazolo-pirazinilo utiles como activadores de guanilato ciclasa soluble. | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| EA201790658A1 (ru) | Производные диарилмочевины в качестве ингибиторов киназы p38 | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| MX2019014876A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| MY194116A (en) | Pharmaceutical compounds | |
| PH12019500460A1 (en) | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers | |
| PH12020550252B1 (en) | Novel phenylpyridine derivative and pharmaceutical composition comprising the same | |
| MX2021015137A (es) | Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos. | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| PH12019502170A1 (en) | Combination of isoindolinone derivatives with sgi-110 | |
| MX385475B (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa | |
| MX2019014438A (es) | Derivados de acidos carboxilicos eficaces como inhibidores de la proteina quinasa. | |
| MX2018001307A (es) | Compuesto de pirrolo[2,3-d]pirimidina o sal del mismo. | |
| EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 |